证券研究报告 | 年报点评报告 gszqdatemark 2025 05 01 年 月 日 美格智能（002881.SZ） 全年业绩创历史新高，持续受益 AI 应用落地 事件：公司发布 2024 年财报及 2025 年一季报，24 全年公司实现营收 29 亿 元，同比增长 37%；实现归母净利润 1.4 亿元，同比增长 110%；扣非归母净 利润约 1.3 亿元，同比增长 244%，三项指标均创历史新高。25Q1 公司实现 营收 10 亿元，同比增长 74%；归母净利润 0.5 亿元，同比大幅增长 616%。 24 年业绩创历史新高，三大主要下游应用赛道均实现营收增长。从下游分类 来看，智能网联车领域营收保持高速增长态势，智能网联车业务营收占比持续 提升，主要得益于公司面向车载核心客户的 5G 智能座舱模组和车规级通信模 组，均实现持续稳定大批量出货；IoT 行业受海外客户智能化需求、国内端侧 AI 新应用推动，继续呈现增长态势，营收占比保持相对平稳；FWA 行业整体 营收规模小幅扩大。三大赛道景气度共振推动公司业绩持续增长。 毛利率略有下滑，成本管控能力进一步提升。24 全年公司整体毛利率为 17%， 较去 ...

Investment Rating - The investment rating for the company is "Buy (Maintain)" [5] Core Views - The company is facing significant pressure on its performance, with a projected revenue decline of 20.5% in 2024 and a further decline of 31.6% in Q1 2025. The net profit attributable to the parent company is expected to decrease by 11.9% to 1.95 billion yuan in 2024 and by 23.6% to 610 million yuan in Q1 2025 [1][4] - The company is adjusting its channel strategy and enhancing product innovation to cope with market challenges. This includes closing inefficient stores and increasing online business efforts [2][3] - The company is focusing on producing trendy products and enhancing its smart manufacturing capabilities to meet consumer demands [3] - The company is implementing deep reforms to promote long-term development, with a focus on high-quality growth [4] Financial Performance - In 2024, the company achieved a revenue of 567.9 billion yuan, down 20.5% year-on-year, with a gross margin of 8.9%, an increase of 0.6 percentage points [1] - The net profit attributable to the parent company for 2024 is projected to be 1.95 billion yuan, a decrease of 11.9% year-on-year [1] - For Q1 2025, the company expects a revenue of 175.2 billion yuan, down 31.6% year-on-year, with a net profit of 610 million yuan, down 23.6% [1] Operational Strategy - The company is reducing the number of physical stores while enhancing its online presence, with a total of 5,838 marketing outlets at the end of 2024, a net decrease of 156 stores [2] - The company is also focusing on product innovation by launching series themed around national trends and collaborating with well-known IPs [3] - The company is enhancing its operational capabilities, with inventory decreasing by 4.1% to 11.82 billion yuan by the end of 2024 [3] Future Outlook - The company anticipates a continued decline in performance for 2025, with a projected revenue drop of 24% [4] - The long-term strategy includes optimizing channels and products to lay a foundation for future growth [4] - The company expects net profits for 2025 to be 1.48 billion yuan, a decrease of 24% [9]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company reported a revenue of 22.3 billion yuan in 2024, a year-on-year increase of 3%, with a net profit attributable to shareholders of -570 million yuan. In Q1 2025, the revenue was 5 billion yuan, a year-on-year decrease of 5%, while the net profit attributable to shareholders was 100 million yuan, a year-on-year increase of 448% [1][2] - The global sales of new energy vehicles reached 18.24 million units in 2024, a year-on-year increase of 24%, with domestic sales at 12.87 million units, up 36%. In Q1 2025, global sales were 4.1 million units, a year-on-year increase of 29%, and domestic sales were 3.08 million units, up 47% [1] - The company's seat business generated 3.1 billion yuan in revenue in 2024, compared to 655 million yuan in the previous year, achieving annual breakeven for the first time [1] Financial Performance - In Q1, the company achieved a gross margin of 16.3%, an increase of 1.6 percentage points year-on-year, and a net profit margin of 2.1%, up 1.8 percentage points year-on-year. This improvement was primarily due to significant growth in the performance of its subsidiary, Grammer [2] - The company had a sufficient order backlog, with 21 projects for passenger car seats confirmed as of February 28, 2025, and a diverse customer base. The company is expanding its production bases in Europe and Southeast Asia [3] - Revenue from new products in 2024 included 400 million yuan from air outlets and 120 million yuan from vehicle refrigerators, with the latter achieving profitability [3] Earnings Forecast and Valuation - The company's net profit forecasts for 2025-2027 have been adjusted to 660 million yuan, 990 million yuan, and 1.35 billion yuan, respectively, with corresponding P/E ratios of 24, 16, and 12 times [3]

Investment Rating - The report maintains a "Buy" rating for the company [4][7]. Core Views - The company's performance is under pressure due to a decline in gross margin and impairment provisions, with projected 2024 revenue of CNY 311.67 billion, down 10.1% year-on-year, and a net profit of CNY 5 billion, down 58.6% year-on-year [1][4]. - Despite the challenges, the company remains the industry leader in sales, with a sales area of 17.966 million square meters in 2024, down 24.7%, and a sales revenue of CNY 323.03 billion, down 23.5% [2][4]. - The company has significantly increased its investment in first-tier cities, with 99% of its investment in core cities and 74% in first-tier cities [3][4]. Financial Performance - The company's total assets decreased by 7.1% year-on-year to CNY 1,335.11 billion, while total liabilities decreased by 9.8% to CNY 992.58 billion [4][11]. - The gross margin for 2024 is expected to decline to 14.1%, down 1.9 percentage points year-on-year, while the net profit margin is projected to be 1.6% [1][11]. - The company’s earnings per share (EPS) for 2025 is projected at CNY 0.43, with a corresponding price-to-earnings (P/E) ratio of 19.5x [4][11]. Market Position - The company has maintained its position as the top seller in the industry for two consecutive years, with a market share of 7.1% in 38 core cities, an increase of 0.3 percentage points year-on-year [2][4]. - The company has improved its cash collection rate, achieving a collection amount of CNY 327.7 billion in 2024, with a collection rate of 101% [2][4]. Investment Strategy - The company plans to focus on high-quality land acquisitions in core cities, with a land acquisition intensity of 21.1% in 2024, down 17.5 percentage points year-on-year, and an equity ratio of 88.1%, the highest in nearly a decade [3][4]. - The report suggests that as the gross margin from land acquisitions recovers, the profit margin from settlements is expected to improve [4].

Investment Rating - The report maintains a "Buy" rating for the company [5][8]. Core Views - The company reported a significant decline in revenue and net profit for 2024, with revenue at 5.511 billion yuan, down 27.26% year-on-year, and net profit at 1.179 billion yuan, down 53.43% year-on-year [1]. - The special integrated circuit segment remains the primary profit source, contributing 91.97% to the net profit, with expectations for high growth in the next 2-3 years as the industry recovers [4]. - The company is focusing on high R&D investment, amounting to 1.286 billion yuan in 2024, which is 23.34% of revenue, to expand its special chip categories [4]. Financial Performance Summary - In 2024, the company achieved a revenue of 5.511 billion yuan, a decrease of 27.26% year-on-year, and a net profit of 1.179 billion yuan, a decrease of 53.43% year-on-year [1][7]. - The special integrated circuit revenue was 2.577 billion yuan, down 42.57% year-on-year, with a net profit of 1.085 billion yuan, down 52.21% year-on-year [2]. - The smart security chip segment saw revenue growth of 3.69% year-on-year, reaching 2.487 billion yuan, with a net profit increase of 11.38% to 293 million yuan [3]. Future Projections - The company forecasts net profits of 1.682 billion yuan, 2.175 billion yuan, and 2.594 billion yuan for 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 33X, 25X, and 21X [5][7]. - The report anticipates a recovery in the special integrated circuit industry, leading to significant growth in the company's performance over the next few years [4].

九阳股份（002242.SZ） 盈利水平环比上行，期待公司景气回升 事件：公司发布 2025 年一季报。公司 25Q1 实现营业收入 20.0 亿元， 同比-3.2%；归母净利润为 1.0 亿元，同比-21.9%；扣非归母净利润为 1.1 亿元，同比-15.1%。 证券研究报告 | 季报点评 gszqdatemark 2025 05 01 年 月 日 核心品类零售端恢复增长态势。根据奥维云数据，2025 年一季度九阳 品牌线上破壁机/空气炸锅品类销额同比+8.1%/+5.0%，市占率同比 提升 2.23pct/0.33pct 至 43.4%/19.8%。 盈利水平环比有所回升。1）毛利率：25Q1 公司毛利率 26.3%，同比 -0.6pct。2）费率端：25Q1 销售/管理费/研发/财务费率分别为 13.1%/4.4%/4.4%/-1.2%，同比变动-0.1pct/持平/+0.2pct/-0.1pct。 3）净利率：25Q1 净利率为 5.0%，同比-1.3pct，环比+4.5pct。 盈利预测与投资建议：考虑到公司 25Q1 利润率环比修复明显，我们 预计公司 2025-2027 年归母净利润分别为 4. ...

Investment Rating - The report maintains a "Buy" rating for the company, with an expected PE of 29 times for 2025 [7]. Core Views - The company is expected to achieve a revenue growth of 10% year-on-year in 2024, reaching 8.98 billion yuan, and a net profit growth of 20%, totaling 700 million yuan [1]. - The consumer business is experiencing rapid growth, with a projected revenue of 4.99 billion yuan in 2024, reflecting a year-on-year increase of 17.1% [3]. - The medical consumables segment is also showing healthy growth, with a revenue of 3.91 billion yuan in 2024, up 1.1% year-on-year [4]. Financial Performance Summary - For 2024, the company expects a gross margin of 47.3%, a decrease of 1.7 percentage points year-on-year, while the net profit margin is projected to increase by 0.6 percentage points to 8.3% [1]. - In Q1 2025, the company reported a revenue of 2.61 billion yuan, a 36% increase year-on-year, with a net profit also up by 36% to 250 million yuan [2]. - The company plans to distribute a cash dividend of 379 million yuan in 2024, with a payout ratio of approximately 54% [1]. Business Segment Analysis - The consumer products segment is driving growth, with core products like wet and dry cotton towels seeing revenue growth of 31% in 2024 and 39% in Q1 2025 [3]. - The medical consumables segment is expanding, particularly after the acquisition of GRI, with a revenue of 1.25 billion yuan in Q1 2025, reflecting a 46.3% year-on-year increase [4]. - The company has increased its store count to 487 by the end of 2024, with a net addition of 76 stores, and the total membership base has grown to nearly 61 million, a 15.8% increase year-on-year [3]. Future Outlook - The company anticipates a revenue growth of 23% in 2025, driven by an 18% increase in the consumer products segment and a 30% increase in the medical consumables segment [5]. - The projected net profit for 2025 is expected to reach 1.05 billion yuan, representing a 51.6% year-on-year growth [6].

Investment Rating - The report maintains a "Buy" rating for the company, with an adjusted profit forecast for 2025-2027 [5][8]. Core Views - The company is expected to face pressure on performance in 2024 due to overseas adjustments, but is anticipated to return to profitability in 2025 as it sheds burdens from its overseas business [5]. - The domestic core brand is leading the industry, with healthy growth in revenue, while overseas operations are expected to continue impacting overall performance negatively [3][5]. Financial Performance Summary - For 2024, the company is projected to have a revenue of 3.04 billion yuan, a year-on-year increase of 4%, but a net loss of 310 million yuan. Adjusted for one-time expenses, the net profit would be approximately 30 million yuan [1]. - In Q1 2025, the company reported a revenue of 690 million yuan, a decrease of 8% year-on-year, but a net profit of 40 million yuan, reflecting a 40% increase compared to the previous year [2]. - The gross margin for 2024 is expected to decline by 0.4 percentage points to 67.4%, with an overall net margin of -8.4% [1]. Market and Brand Analysis - The domestic market is showing robust growth, with a projected revenue increase of 10% in 2024 and 8.1% in Q1 2025 for the core brand [3]. - The company is focusing on enhancing its e-commerce channels, which have shown significant growth, with online sales increasing by 32.4% in 2024 [3]. - The main brands, including ELLASSAY and Laurel, are expected to continue their growth trajectory, with sales increases of 8% and 19% respectively in 2024 [4]. Cash Flow and Inventory Management - The company has effectively managed its cash flow, with a net operating cash flow of 420 million yuan at the end of 2024 [5]. - Inventory levels have decreased, with a year-on-year reduction of 12.3% by the end of 2024, indicating efficient inventory management [5].

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company achieved a significant revenue growth of 26.84% year-on-year in 2024, reaching 5.16 billion yuan, and a net profit of 386 million yuan, marking a 170.04% increase [1][2] - The revenue structure continues to optimize, with pharmaceutical-related revenue accounting for 82.56% of total revenue in 2024, up from 76.15% in 2023 [2] - The company has shown strong performance in its innovative drug pipeline, with Q1 2025 seeing a remarkable growth of 327.73% in innovative drug products [3][4] Financial Performance - In Q4 2024, the company reported a revenue of 1.30 billion yuan, a year-on-year increase of 14.39%, and a net profit of 20 million yuan, up 102.81% [1] - For Q1 2025, the company achieved a revenue of 1.33 billion yuan, a slight increase of 0.05% year-on-year, and a net profit of 153 million yuan, reflecting a 4.83% growth [1] - The overall gross margin for 2024 was 47.42%, slightly down from 47.84% in 2023, attributed to lower margins from newly introduced products and price adjustments [3] Revenue and Profit Forecast - The company is expected to continue its growth trajectory, with projected net profits of 704 million yuan, 888 million yuan, and 1.09 billion yuan for 2025, 2026, and 2027 respectively, representing growth rates of 82.5%, 26.1%, and 22.9% [4][5] - The estimated P/E ratios for 2025, 2026, and 2027 are 20X, 16X, and 13X respectively, indicating a favorable valuation outlook [4] R&D Progress - The company is advancing its R&D efforts, including ongoing clinical trials for various products and achieving consensus with regulatory bodies on clinical trial designs [4]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market index [7]. Core Views - The company is expected to achieve significant revenue growth in 2024, with a projected revenue of CNY 1.0 billion, representing a year-on-year increase of 22%, and a net profit of CNY 190 million, reflecting a 42% increase [1]. - The company is actively expanding its product categories, with new products anticipated to drive rapid growth in 2025 [3]. - The company has a competitive advantage due to its integrated domestic supply chain and successful international production base expansion [4]. - The financial forecasts for 2025 to 2027 indicate strong growth in both revenue and net profit, with net profit expected to reach CNY 272 million in 2025, a 47.1% increase year-on-year [5][6]. Summary by Sections Financial Performance - In 2024, the company is projected to have a gross margin of 33.7%, with a net profit margin of 18.9% [1]. - For Q1 2025, the company reported a revenue of CNY 360 million, a 30% increase year-on-year, and a net profit of CNY 100 million, marking a 148% increase [2]. - The company plans to distribute cash dividends totaling CNY 28 million in 2024, with a payout ratio of approximately 15% [1]. Product and Market Expansion - The company has established stable long-term partnerships with major clients, including Decathlon, and expects its international sales to grow significantly [3]. - The revenue breakdown for 2024 shows that inflatable mattresses, bags, and other categories are expected to contribute significantly, with respective year-on-year growth rates of 14%, 31%, and 48% [3]. Operational Efficiency - The company is enhancing its production capabilities in various regions, including China, Vietnam, and Cambodia, which is expected to improve profitability [4]. - Inventory levels have increased, with a year-on-year rise of 34.4% by the end of 2024, but inventory turnover days have decreased, indicating effective inventory management [4]. Future Outlook - The company anticipates continued strong growth in its core inflatable mattress business and expects production capacity in overseas subsidiaries to ramp up smoothly [5]. - The financial projections suggest a robust growth trajectory, with expected revenues of CNY 1.37 billion in 2025, a 36.7% increase from 2024 [6].